Integrin Alpha4beta1 Agents Modulating Hematopoietic Cell Adhesion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective modulation of hematopoietic progenitor cell adhesion, migration, and differentiation, which are crucial for treating diseases but also contribute to undesirable consequences like tumor growth and inflammatory diseases.
Innovation Solution
The use of agents that alter the binding of integrin α4β1 to its ligands, such as VCAM and fibronectin, to specifically target and manipulate hematopoietic progenitor cell adhesion and migration to target tissues, and to direct their differentiation into specific cell types.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hematopoietic progenitor cells are used to promote tissue repair and neovascularization, then therapeutic potential is enhanced, but undesirable consequences such as tumor growth and inflammatory disease are promoted
Solution Approach 1:
The patent applies local quality by using agents that specifically alter integrin α4β1 binding in targeted tissues. The agents are designed to modulate hematopoietic progenitor cell behavior locally at the target site rather than systemically, allowing therapeutic effects in damaged tissues while minimizing unwanted effects in other organs. This selective local modulation addresses the contradiction by enhancing repair where needed while reducing harmful angiogenesis elsewhere.
Solution Approach 2:
The patent employs parameter changes by using agents that modify the binding affinity of integrin α4β1 to its ligands. By changing this specific biochemical parameter, the patent can control hematopoietic progenitor cell adhesion, migration, and differentiation. This allows precise regulation of cell behavior to promote therapeutic outcomes while suppressing harmful effects, resolving the contradiction between beneficial and harmful angiogenesis.
2Manufacturing precision
If agents that alter integrin α4β1 binding are used to control hematopoietic progenitor cell behavior, then targeted tissue repair is enhanced, but device complexity increases
Solution Approach 1:
The patent uses agents as intermediaries that mediate between the administered substance and the hematopoietic progenitor cells. These agents specifically bind to integrin α4β1 or its ligands, acting as a bridge to control cell adhesion and migration. By using this intermediary mechanism, the patent achieves precise control over cell behavior without requiring direct manipulation of complex cellular processes, thus enhancing targeted repair while managing overall system complexity.
3Productivity
If hematopoietic progenitor cell migration to target tissue is increased, then tissue repair is enhanced, but adhesion to non-target tissues may increase causing unwanted effects
Solution Approach 1:
The patent applies preliminary action by using agents that pre-condition the target tissue environment or pre-modify hematopoietic progenitor cell properties before migration occurs. The agents are administered in advance to create favorable conditions for selective adhesion to target tissues while preventing unwanted adhesion to non-target tissues. This proactive approach enhances repair efficiency while minimizing harmful side effects by establishing selective adhesion patterns before migration begins.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for controlled modulation of hematopoietic progenitor cell behavior, enhancing therapeutic potential while minimizing adverse effects, by promoting targeted tissue repair and reducing unwanted angiogenesis.
Implementation Method 1
one or more agent that alters specific binding of integrin α4β1 to an integrin α4β1 ligand
Data Source
AI summary
The present invention satisfies the need in the art by providing methods for altering hematopoietic progenitor cell adhesion and/or migration to a target tissue, and for altering hematopoietic progenitor cell differentiation into a second cell type. The invention also provides methods for screening test compounds for altering the level of hematopoietic progenitor cell adhesion and/or migration to a target tissue, and for altering hematopoietic progenitor cell differentiation into a second cell type. The invention further provides methods for isolating hematopoietic progenitor cells.